Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/29271| Title: | Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. | Authors: | Doocey R.;Johnston A.;Armytage T.;Lee C.;Cochrane T.;Berkhahn L.;Weinkove R.;Harrison S.J.;Webber N.;Lee H.-P.;Chapman S.;Campbell B.A.;Gibbs S.D.J.;Hamad N.;Di Ciaccio P.;McCaughan G.;Trotman J.;Ho P.J.;Cheah C.Y.;Gangatharan S.;Wight J.;Ku M.;Quach H.;Gasiorowski R.;Polizzotto M.N.;Prince H.M.;Mulligan S.;Tam C.S.;Gregory G. ;Hapgood G.;Spencer A.;Dickinson M.;Latimer M. | Monash Health Department(s): | Haematology | Institution: | (Di Ciaccio, McCaughan, Polizzotto, Hamad) Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia (Di Ciaccio, McCaughan, Polizzotto, Hamad) University of New South Wales, Sydney, NSW, Australia (McCaughan, Trotman, Ho, Gasiorowski, Mulligan, Hamad) University of Sydney, Sydney, NSW, Australia (Trotman, Gasiorowski) Department of Haematology, Concord Repatriation General Hospital, Sydney, NSW, Australia (Ho) Department of Haematology, Royal Prince Alfred Hospital, Sydney, NSW, Australia (Cheah) Department of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia (Cheah) Department of Haematology, Pathwest Laboratory Medicine, Perth, WA, Australia (Cheah, Gangatharan) University of Western Australia, Perth, WA, Australia (Gangatharan) Department of Haematology, Fiona Stanley Hospital, Perth, WA, Australia (Wight) Townsville University Hospital, Townsville, QLD, Australia (Wight, Ku, Quach, Prince, Tam, Spencer, Dickinson, Harrison, Campbell) University of Melbourne, Melbourne, VIC, Australia (Ku, Quach, Tam) Department of Haematology, St Vincent's Hospital, Melbourne, VIC, Australia (Polizzotto) The Kirby Institute, University of New South Wales, Sydney, NSW, Australia (Prince, Tam, Dickinson, Harrison) Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia (Prince) Department of Haematology, Epworth Healthcare, Melbourne, VIC, Australia (Mulligan) Department of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia (Gregory) Department of Haematology, Monash Health, Melbourne, VIC, Australia (Hapgood) Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia (Spencer) Department of Haematology, The Alfred Hospital, Melbourne, VIC, Australia (Latimer) Department of Haematology, Canberra Hospital, Canberra, ACT, Australia (Johnston) Department of Haematology, The Royal Hobart Hospital, Hobart, TAS, Australia (Johnston) University of Tasmania, Hobart, TAS, Australia (Armytage) Department of Haematology, Gosford Hospital, Gosford, NSW, Australia (Lee) Department of Haematology, Queen Elizabeth Hospital, Adelaide, SA, Australia (Cochrane) Department of Haematology, Gold Coast University Hospital, Southport, QLD, Australia (Cochrane) Griffith University, Brisbane, QLD, Australia (Berkhahn, Doocey) Department of Haematology, The Auckland City Hospital, Auckland, New Zealand (Berkhahn) University of Auckland, Auckland, New Zealand (Weinkove) Department of Haematology, Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand (Weinkove) Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand (Webber) Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia (Lee) Department of Haematology, Flinders Medical Centre, Southern Adelaide Local Health Network, Adelaide, SA, Australia (Chapman) Department of Infectious Diseases, St Vincent's Hospital, Sydney, NSW, Australia (Campbell) Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (Gibbs) Department of Haematology, Eastern Health, Melbourne, VIC, Australia (Gibbs) Monash University, Melbourne, VIC, Australia | Issue Date: | 20-Jun-2020 | Copyright year: | 2020 | Publisher: | Blackwell Publishing | Place of publication: | Australia | Publication information: | Internal Medicine Journal. 50 (6) (pp 667-679), 2020. Date of Publication: 01 Jun 2020. | Journal: | Internal Medicine Journal | Abstract: | The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources.Copyright © 2020 Royal Australasian College of Physicians | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/imj.14859 | PubMed URL: | 32415723 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32415723] | ISSN: | 1444-0903 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/29271 | Type: | Article | Subjects: | rituximab/dt [Drug Therapy] vincristine/dt [Drug Therapy] vincristine sulfate/cb [Drug Combination] vincristine sulfate/cm [Drug Comparison] vincristine sulfate/dt [Drug Therapy] bcl2 gene BCL6 gene gene rearrangement Herpes simplex virus human *lymphoma maintenance therapy mantle cell lymphoma/dt [Drug Therapy] multiple myeloma/th [Therapy] *myeloma/th [Therapy] New Zealand oncogene myc *pandemic patient attitude priority journal salvage therapy screening test telehealth vaccination virus shedding virus transmission cyclophosphamide/cb [Drug Combination] cyclophosphamide/cm [Drug Comparison] cyclophosphamide/dt [Drug Therapy] cytarabine/cb [Drug Combination] cytarabine/dt [Drug Therapy] doxorubicin/cb [Drug Combination] doxorubicin/cm [Drug Comparison] doxorubicin/dt [Drug Therapy] etoposide/cb [Drug Combination] etoposide/dt [Drug Therapy] growth factor ibrutinib/dt [Drug Therapy] ifosfamide/cb [Drug Combination] ifosfamide/dt [Drug Therapy] immunoglobulin methotrexate/cb [Drug Combination] methotrexate/dt [Drug Therapy] Myc protein/ec [Endogenous Compound] prednisolone/cb [Drug Combination] prednisolone/cm [Drug Comparison] prednisolone/dt [Drug Therapy] prednisone/cb [Drug Combination] prednisone/cm [Drug Comparison] prednisone/dt [Drug Therapy] protein bcl 2/ec [Endogenous Compound] protein bcl 6/ec [Endogenous Compound] rituximab/cb [Drug Combination] rituximab/cm [Drug Comparison] venetoclax/dt [Drug Therapy] vincristine/cb [Drug Combination] vincristine/cm [Drug Comparison] AL amyloidosis antifungal therapy article Australian autologous stem cell transplantation B cell lymphoma/dt [Drug Therapy] Burkitt lymphoma/dt [Drug Therapy] cancer grading cancer immunotherapy cancer radiotherapy cancer recurrence *chronic lymphatic leukemia/dt [Drug Therapy] *coronavirus disease 2019 diagnostic test diffuse large B cell lymphoma/rt [Radiotherapy] follicular lymphoma/dt [Drug Therapy] rituximab vincristine vincristine sulfate bcl2 gene BCL6 gene gene rearrangement Herpes simplex virus lymphoma maintenance therapy mantle cell lymphoma multiple myeloma myeloma New Zealand oncogene myc pandemic patient attitude salvage therapy screening test telehealth vaccination virus shedding virus transmission cyclophosphamide cytarabine doxorubicin etoposide growth factor ibrutinib ifosfamide immunoglobulin methotrexate Myc protein prednisolone protein bcl 2 protein bcl 6 rituximab venetoclax vincristine AL amyloidosis antifungal therapy Australian autologous stem cell transplantation B cell lymphoma Burkitt lymphoma cancer grading cancer immunotherapy cancer radiotherapy cancer recurrence chronic lymphatic leukemia coronavirus disease 2019 diagnostic test diffuse large B cell lymphoma follicular lymphoma priority journal salvage therapy screening test telehealth vaccination virus shedding virus transmission Australian Article antifungal therapy AL amyloidosis *myeloma / *therapy cancer grading cancer immunotherapy cancer radiotherapy cancer recurrence B cell lymphoma / drug therapy New Zealand oncogene myc *pandemic patient attitude *lymphoma maintenance therapy mantle cell lymphoma / drug therapy multiple myeloma / therapy Burkitt lymphoma / drug therapy autologous stem cell transplantation *chronic lymphatic leukemia / *drug therapy *coronavirus disease 2019 diagnostic test diffuse large B cell lymphoma / radiotherapy follicular lymphoma / drug therapy gene rearrangement Herpes simplex virus human |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.